Kardigan

Kardigan's $400M IPO Fuels Cardiovascular Drug Development Amid Biotech Funding Surge

Kardigan's $400 million IPO marks a significant market entry, bolstering its late-stage cardiovascular pipeline. This event underscores robust investor confidence in biotech addressing unmet medical needs, particularly in heart disease. For industry leaders, it signals new competitive dynamics, potential partnership opportunities, and increased demand for specialized supply chain services in advanced therapeutics.